CD274 and non-small cell lung carcinoma: Preclinical studies indicated that cisplatin-resistant non-small cell lung cancer (NSCLC) cell lines were resistant to NK cell killing via upregulated programmed death ligand 1 (PD-L1) and decreased NKG2D ligand expression (39).